David L. Sutcliffe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
David L. Sutcliffe has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Ryan Butts
Department of Pediatrics Children's Medical Center of Dallas/University of Texas Southwestern Dallas Texas USA
6 shared publications - Ryan Robert Davies
UT Southwestern Med Ctr, Dept Cardiovasc & Thorac Surg, 1935 Med Dist Dr,MC B3-410, Dallas, TX 75235 USA
4 shared publications Angela Lorts
Cincinnati Children’s Hospital Heart Institute, Department of Pediatrics, University of Cincinnati College of Medicine, OH (A.M.L., A.L., D.L.S.M., L.S.).
3 shared publications- Anna Joong
Lurie Children's Hospital of Chicago
3 shared publications - David M. Peng
University of Michigan Ann Arbor Michigan USA
3 shared publications - David N. Rosenthal
Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California
3 shared publications
Latest Publications
- 15 June 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (11) , 1859-1868
Explantation of durable ventricular assist device for myocardial functional recovery in children: A report from the ACTION registry
- 15 June 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (11) , 1859-1868
Explantation of durable ventricular assist device for myocardial functional recovery in children: A report from the ACTION registry
- 18 January 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (4) , 530-540
The ACTION VAD registry: A collective five-year experience
- 18 January 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (4) , 530-540
The ACTION VAD registry: A collective five-year experience
- Open Access
- 19 November 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (8) , e14894
Decreasing Endomyocardial Biopsy Frequency in Pediatric Heart Transplantation Using A Rejection Risk Prediction Score—A Single Center Study
Background: Rejection remains an important cause of morbidity and mortality after pediatric heart transplantation (HT). Endomyocardial biopsy (EMB) is the gold standard for rejection diagnosis, but it comes with procedural risk. The frequency of EMB varies significantly across centers. Since April 2018, our center's surveillance EMB schedule is based on a rejection risk prediction score employing age, pre‐HT diagnosis, and panel reactive antibodies (PRA). We aimed to evaluate outcomes in the 1st year post‐HT before and after risk score implementation.Methods: Patients who underwent HT at our center at ≤ 18 years of age from January 2015 to December 2020 were reviewed. The primary endpoint was rejection‐free survival at 1 year‐post‐ HT. Clinical characteristics were compared for patients transplanted in Era 1 (January 2015–April 2018) and Era 2 (April 2018–December 2020). Cumulative 1‐year survival free from rejection and from rejection with hemodynamic compromise (RHC) was compared between eras using Kaplan‐Meier survival analysis.Results: 115 patients underwent HT during our study period (52 in Era 1 and 63 in Era 2). There was an increase in VAD utilization between eras (19% in Era 1 vs. 40% in Era 2, p = 0.025), but otherwise no significant difference in demographic or clinical variables between the two eras. No statistically significant difference in freedom from rejection or freedom from RHC was identified between the two eras. There was a 60% reduction in the median number of EMB per patient in the first year post‐HT after employing the score (5 in Era 1 vs. 2 in Era 2, p < 0.001).Conclusions: After employing a rejection risk prediction score, our center decreased the frequency of EMB without worsening early post‐HT outcomes, thus establishing the clinical applicability of this tool.
- 19 November 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (8) , e14894
Open AccessDecreasing Endomyocardial Biopsy Frequency in Pediatric Heart Transplantation Using A Rejection Risk Prediction Score—A Single Center Study
Background: Rejection remains an important cause of morbidity and mortality after pediatric heart transplantation (HT). Endomyocardial biopsy (EMB) is the gold standard for rejection diagnosis, but it comes with procedural risk. The frequency of EMB varies significantly across centers. Since April 2018, our center's surveillance EMB schedule is based on a rejection risk prediction score employing age, pre‐HT diagnosis, and panel reactive antibodies (PRA). We aimed to evaluate outcomes in the 1st year post‐HT before and after risk score implementation.Methods: Patients who underwent HT at our center at ≤ 18 years of age from January 2015 to December 2020 were reviewed. The primary endpoint was rejection‐free survival at 1 year‐post‐ HT. Clinical characteristics were compared for patients transplanted in Era 1 (January 2015–April 2018) and Era 2 (April 2018–December 2020). Cumulative 1‐year survival free from rejection and from rejection with hemodynamic compromise (RHC) was compared between eras using Kaplan‐Meier survival analysis.Results: 115 patients underwent HT during our study period (52 in Era 1 and 63 in Era 2). There was an increase in VAD utilization between eras (19% in Era 1 vs. 40% in Era 2, p = 0.025), but otherwise no significant difference in demographic or clinical variables between the two eras. No statistically significant difference in freedom from rejection or freedom from RHC was identified between the two eras. There was a 60% reduction in the median number of EMB per patient in the first year post‐HT after employing the score (5 in Era 1 vs. 2 in Era 2, p < 0.001).Conclusions: After employing a rejection risk prediction score, our center decreased the frequency of EMB without worsening early post‐HT outcomes, thus establishing the clinical applicability of this tool.
- 1 February 2023
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 16 (2) , 219-228
Considerations for Advanced Heart Failure Consultation in Individuals With Fontan Circulation: Recommendations From ACTION
Individuals with Fontan circulation are at risk of late mortality from both cardiac and noncardiac causes. Despite the known risk of mortality, referral indications for advanced heart failure care vary between centers, and many individuals die from Fontan circulation-related complications either after late consideration for advanced heart failure therapies or having never seen a heart failure specialist. There is a critical need for guidelines to direct appropriately timed referral for advanced heart failure consultation. The Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Fontan Committee has developed recommended thresholds for advanced heart failure referral to guide primary cardiologists. These recommendations are divided into 4 categories of clinical Fontan circulatory dysfunction including (1) cardiac/systemic ventricular dysfunction, (2) Fontan pathway dysfunction, (3) lymphatic dysfunction, and (4) extracardiac dysfunction.
- 1 February 2023
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 16 (2) , 219-228
Considerations for Advanced Heart Failure Consultation in Individuals With Fontan Circulation: Recommendations From ACTION
Individuals with Fontan circulation are at risk of late mortality from both cardiac and noncardiac causes. Despite the known risk of mortality, referral indications for advanced heart failure care vary between centers, and many individuals die from Fontan circulation-related complications either after late consideration for advanced heart failure therapies or having never seen a heart failure specialist. There is a critical need for guidelines to direct appropriately timed referral for advanced heart failure consultation. The Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Fontan Committee has developed recommended thresholds for advanced heart failure referral to guide primary cardiologists. These recommendations are divided into 4 categories of clinical Fontan circulatory dysfunction including (1) cardiac/systemic ventricular dysfunction, (2) Fontan pathway dysfunction, (3) lymphatic dysfunction, and (4) extracardiac dysfunction.
- 19 September 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (2) , 246-254
Initial multicenter experience with ventricular assist devices in children and young adults with muscular dystrophy: An ACTION registry analysis
- 19 September 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (2) , 246-254
Initial multicenter experience with ventricular assist devices in children and young adults with muscular dystrophy: An ACTION registry analysis
- 7 April 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (4) , S108
Continuous Flow Paracorporeal Support in Children: A Single Center Experience
- 7 April 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (4) , S108
Continuous Flow Paracorporeal Support in Children: A Single Center Experience
- 7 April 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (4) , S109
Remote Monitoring of Pediatric VAD Patients: Early Recognition for Improved Management
- 7 April 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (4) , S109
Remote Monitoring of Pediatric VAD Patients: Early Recognition for Improved Management
- 5 March 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (3) , e13990
Right heart failure considerations in pediatric ventricular assist devices
Right heart failure (RHF) is a vexing problem in children after left ventricular assist device (LVAD) implantation that can negatively impact transplant candidacy and survival. Anticipation, prevention, early identification and appropriate medical and device management of RHF are important to successful LVAD outcomes. However, there is limited pediatric evidence to guide practice. This pediatric‐focused review summarizes the relevant literature and describes the harmonized approach to RHF from the Advanced Cardiac Therapies Improving Outcomes Network (ACTION). This review seeks to improve RHF outcomes through the sharing of best practices and experience across the pediatric VAD community.
- 5 March 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (3) , e13990
Right heart failure considerations in pediatric ventricular assist devices
Right heart failure (RHF) is a vexing problem in children after left ventricular assist device (LVAD) implantation that can negatively impact transplant candidacy and survival. Anticipation, prevention, early identification and appropriate medical and device management of RHF are important to successful LVAD outcomes. However, there is limited pediatric evidence to guide practice. This pediatric‐focused review summarizes the relevant literature and describes the harmonized approach to RHF from the Advanced Cardiac Therapies Improving Outcomes Network (ACTION). This review seeks to improve RHF outcomes through the sharing of best practices and experience across the pediatric VAD community.
- 14 June 2020
- Published by Wiley in Pediatric Transplantation
- Vol. 24 (6) , e13764
A comprehensive strategy in donor acceptance: Impact on pediatric waitlist and heart transplant outcomes
Significant inter‐ and intra‐center practice variability is present in pediatric donor heart acceptability. This may contribute to variation in the donor refusal rate and may impact waitlist time, morbidity, mortality, and transplant rates. In order to reduce practice variability, our center developed and implemented a comprehensive strategy regarding donor acceptance in September 2017. The aim of this study was to assess the impact of this strategy on waitlist time and outcomes as well as early post‐transplant outcomes. We performed a single‐center, retrospective analysis of all pediatric (P = .006. The number of donor refusals was lower in Group 2 (1, IQR 0‐2.2) vs Group 1 (4, IQR 2‐19); P < .001. The percentage of refused donors with normal function (Left ventricular ejection fraction > 50%) was lower in Group 2 vs Group 1 (53% vs 84%; P < .001). Difference in removal from the waitlist for death or deterioration in Group 2 vs Group 1 (n = 2, 7% vs n = 7, 20%, P = .18) did not reach statistical significance. There was no difference in post‐transplant outcomes between groups. The waitlist time and donor refusals significantly decreased after implementation of a comprehensive donor acceptance strategy without impacting transplant outcomes. This analysis supports the need for a comprehensive approach to donor organ acceptance within a pediatric transplant center.
- 14 June 2020
- Published by Wiley in Pediatric Transplantation
- Vol. 24 (6) , e13764
A comprehensive strategy in donor acceptance: Impact on pediatric waitlist and heart transplant outcomes
Significant inter‐ and intra‐center practice variability is present in pediatric donor heart acceptability. This may contribute to variation in the donor refusal rate and may impact waitlist time, morbidity, mortality, and transplant rates. In order to reduce practice variability, our center developed and implemented a comprehensive strategy regarding donor acceptance in September 2017. The aim of this study was to assess the impact of this strategy on waitlist time and outcomes as well as early post‐transplant outcomes. We performed a single‐center, retrospective analysis of all pediatric (P = .006. The number of donor refusals was lower in Group 2 (1, IQR 0‐2.2) vs Group 1 (4, IQR 2‐19); P < .001. The percentage of refused donors with normal function (Left ventricular ejection fraction > 50%) was lower in Group 2 vs Group 1 (53% vs 84%; P < .001). Difference in removal from the waitlist for death or deterioration in Group 2 vs Group 1 (n = 2, 7% vs n = 7, 20%, P = .18) did not reach statistical significance. There was no difference in post‐transplant outcomes between groups. The waitlist time and donor refusals significantly decreased after implementation of a comprehensive donor acceptance strategy without impacting transplant outcomes. This analysis supports the need for a comprehensive approach to donor organ acceptance within a pediatric transplant center.